Plain-English translation of NCT06320223 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →The PROMISE Registry is collecting data from up to 10,000 prostate cancer patients who have undergone a type of imaging scan called PSMA PET. Researchers want to understand how well this scan predicts survival and how it compares to other ways doctors assess prostate cancer risk. By studying patterns across many patients, the team hopes to help doctors make better treatment decisions for people with prostate cancer at all stages.
Currently, doctors use several different methods to predict how prostate cancer will progress and to guide treatment choices. This research aims to determine whether the PSMA PET scan is a better predictor of survival than existing methods, which could help doctors personalize treatment plans and improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
This is a registry study, meaning you would not need to visit a hospital repeatedly or receive any new treatments. Instead, researchers would gather information from your existing medical records, including your PSMA PET scan results and survival follow-up data over at least 3 years. There are no additional procedures or medications involved—you are helping by allowing doctors to use your medical history to improve understanding of how this scan predicts outcomes.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Germany